The information on this page applies only to the United States
The acquisition of Bausch + Lomb in 2013 positioned Valeant to capitalize on growing eye health trends driven by an aging patient population, an increased rate of diabetes and demand from emerging markets.
Bausch + Lomb offers a broad portfolio of eye health products, including contact lenses and lens care products, pharmaceuticals, intraocular lenses and surgical equipment. Its contact lens offerings include such well-known brand names as Biotrue® ONEday, PureVision®, SofLens®, Boston®, Optima® and Naturelle™. Lens care products include Biotrue® and the renu® brand of multi-purpose disinfectants for soft contact lenses, as well as the Boston® line of products for cleaning gas-permeable contact lenses.
The company’s eye health-related pharmaceutical products (brand, generic and over-the-counter) treat a range of eye conditions including glaucoma, eye allergies, conjunctivitis, dry eye and retinal diseases.
Its line of proprietary pharmaceutical products includes the antibacterial eye drops Besivance® (besifloxacin ophthalmic suspension) 0.6%; steroid eye drops Lotemax® (loteprednol etabonate ophthalmic ointment) 0.5%, Alrex® (loteprednol etabonate ophthalmic suspension) 0.2% and Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension); Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg for treatment of non-infectious uveitis affecting the posterior segment of the eye.
Bausch + Lomb’s pharmaceutical portfolio also includes Bepreve® (bepotastine besilate ophthalmic solution) 1.5% for allergic conjunctivitis, Istalol® (timolol maleate ophthalmic solution) 0.5% for glaucoma, Vitrase® (hyaluronidase Injection) Ovine, 200 USP Units/mL, a spreading agent, and Prolensa® (bromfenac ophthalmic solution) 0.07% for postoperative inflammation and pain in patients who have undergone cataract surgery.
Leading OTC products include Ocuvite® and PreserVision® eye vitamin and mineral supplements, Soothe® dry eye drops, PeroxiClear®, a peroxide-based lens care solution, and Alaway® eye drops. Additional products include Lacrisert® (hydroxypropyl cellulose ophthalmic insert) for treatment of dry eye syndrome; Timoptic® 0.25% and 0.5% (timolol maleate ophthalmic solution) in Ocudose® for treatment of high eye-pressure in patients with glaucoma; Macugen® (pegaptanib sodium injection) for treatment of wet age-related macular degeneration; and Visudyne® (verteporfin for injection), approved for certain forms of wet age-related macular degeneration.